Roche's Tecentriq Approved As Second-Line in Lung Cancer: Implications For Bristol-Myers Squibb
FDA approved Roche's (U.S. ADR, OTCBB: RHHBY) Tecentriq, a checkpoint inhibitor that targets PD-L1 as a second-line therapy in metastatic non-small...
214 Views
Big Pharma Fails to Heed Its Mistakes
GlaxoSmithKline and other big pharma companies have repeatedly been convicted and fined for unethical business practices - mainly offering bribes -...
281 Views
2016 US Elections Scenario Two: Donald Trump Wins
A US election fought under moderately favourable economic conditions, with a Republican electorate divided and openly unhappy with its...
219 Views
2016 US Elections Scenario One: Hillary Clinton Wins
A US election fought under moderately favourable economic conditions, with a Republican electorate divided and openly unhappy with its...
202 Views
US Stock Market Seasonality: Shemitah Redux, The Afterparty
Almost exactly a year ago I wrote a piece on stock market seasonality titled Stock Market Seasonality - Januaries, SuperBowls, Third Years,...
227 Views